Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Naked Truth - Big Kahuna a Myth -- Ignore unavailable to you. Want to Upgrade?

To: pater tenebrarum who wrote (54093)	7/31/1999 3:41:00 PM
From: John Pitera	Read Replies (1) \| Respond to of 86076

AMGN and BGEN have been strong performers, AMGN has given us 2 opportunities to buy it at it's 200 dma in the last 18 months. I notice that they are on SSB's 10 stocks list as well. Salomon Smith Barney 1999-2000 TEN+ List Brief: Biotechnology July 20, 1999 US07G220 (AMGN, 1-H) Price $73.44 Dividend N/A 12-Month Range $80-$30 Yield N/A EPS 2000E $2.26 P/E 2000E 30.7x EPS 1999E $1.96 P/E 1999E 35.3x EPS 1998A $1.63 5-YR. EPS Growth 20% Since we selected Amgen for the SSB TEN+ List, the company reported a major upside EPS surprise for 2Q99. The strength of the quarter prompted us to raise our EPS estimates for 1999, 2000, and 2001. We also raised our price target to $112 from $100. Amgen has two blockbusters, Epogen and Neupogen, both of which have annual sales of over $1 billion. We expect strong sales growth for both . Two Late-Stage Products Expected to Hit the Market in 2001. 1) NESP, a second-genera- tion EPO, is currently in phase III trials. 2) Abarelix, an antagonist of GnRH, is currently in phase III trials in prostate cancer. Promising Pipeline. Amgen has a broad prod- uct pipeline which includes sustained-duration Neupogen, second-generation leptin for obesity, sTNF-R1/IL-1 for RA and neuroimmunophilins initially for Parkinson's.